Perrigo second quarter sales rise 10% to $221.7 mil., net income up 13%.
This article was originally published in The Tan Sheet
Executive Summary
PERRIGO SALES RISE 10% TO $221.7 MIL. IN SECOND QUARTER on double-digit sales increases in the company's OTC and nutritional businesses. The private label firm said the gain in OTC sales reflected a severe cough, cold and flu season through the end of the second quarter (ended Dec. 31) that contributed to higher sales in the cough/cold and analgesic categories
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.